Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Substance Withdrawal Clear all
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996
View directory record Official record
Conditions
Nicotine Dependence
Interventions
zonisamide, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

NCT00218127
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Levoacetyl Methadol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
25 Years to 55 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

NCT02210195
View directory record Official record
Conditions
Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
Interventions
aprepitant, Placebo, Manual-guided behavioral counseling
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers

NCT05335915
View directory record Official record
Conditions
Nicotine Withdrawal, Nicotine Addiction, Drug Effect
Interventions
Nicotine, Cigarette
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Not yet recruiting Phase 1 Interventional

Cannabis and Opioid Use Disorder, Study 2

NCT07661446
View directory record Official record
Conditions
Opioid Use Disorders, Cannabis Use
Interventions
Inhaled Cannabis, Intranasal Opioid
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Up to 4 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 5, 2026, 2:30 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Recruiting Phase 3 Interventional

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478
View directory record Official record
Conditions
Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Interventions
Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 5, 2026, 2:30 PM EDT
Withdrawn Not applicable Interventional

Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal

NCT04159909
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Use Disorder
Interventions
Transcutaneous Nerve Stimulation, Sham Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder

NCT05226130
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 5, 2026, 2:30 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Not yet recruiting No phase listed Observational

Development of an Opioid Withdrawal Clinical Outcome Assessment

NCT07094672
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use

NCT06410287
View directory record Official record
Conditions
Nurse's Role, Stigma, Social, Implicit Bias
Interventions
ArtSpective
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Saint Cloud, Minnesota • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

NCT00158132
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Propranolol, Amantadine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
MN-166 (50 mg) First, Placebo First
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional

Tobacco Cessation in Postmenopausal Women (Part I) - 1

NCT00061061
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Behavior Therapy
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 79 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Racial Differences in Circadian and Sleep Mechanisms for Nicotine Dependence, Craving, and Withdrawal

NCT03968900
View directory record Official record
Conditions
Smoking, Sleep Disturbance, Nicotine Dependence
Interventions
Sleep restriction condition, Sleep extension condition
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome

NCT05937594
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Interventions
Buccal swab saliva for further genetic testing
Genetic
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Day to 5 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 5, 2026, 2:30 PM EDT